Kim Stratton - Novozymes Director
| NVZMF Stock | USD 52.51 1.94 3.56% |
Director
Ms. Kim Stratton was Independent Director at NOVOZYMES AS since February 22, 2017. She is Member of the Nomination and Remuneration Committee. She also serves as Board Member of European Federation of Pharmaceutical Industries and Associations . She has international commercial experience within sales and marketing, emerging markets, innovation pipeline management and sustainability. since 2017.
| Age | 56 |
| Tenure | 7 years |
| Phone | 45 44 46 00 00 |
| Web | https://www.novozymes.com |
Novozymes Management Efficiency
The company has return on total asset (ROA) of 0.1062 % which means that it generated a profit of $0.1062 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.2789 %, meaning that it generated $0.2789 on every $100 dollars invested by stockholders. Novozymes' management efficiency ratios could be used to measure how well Novozymes manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Annette Winkler | Air Liquide SA | 57 | |
| Matthew Thornton | Sherwin Williams Co | 62 | |
| Michele Hooper | PPG Industries | 66 | |
| Ulf Schneider | Dupont De Nemours | 49 | |
| Michael Lamach | PPG Industries | 57 | |
| Jeff Fettig | Sherwin Williams Co | 64 | |
| Evert Henkes | Air Products and | 71 | |
| Amy Brady | Dupont De Nemours | 54 | |
| Eleuthere Pont | Dupont De Nemours | 53 | |
| Terrence Curtin | Dupont De Nemours | 52 | |
| Arthur Anton | Sherwin Williams Co | 63 | |
| Paul Skinner | Air Liquide SA | 70 | |
| Victoria Reich | Ecolab Inc | 63 | |
| Shari Ballard | Ecolab Inc | 54 | |
| Scott Minder | PPG Industries | N/A | |
| Leslie Biller | Ecolab Inc | 70 | |
| Robert Brown | Dupont De Nemours | 65 | |
| Hugh Grant | PPG Industries | 62 | |
| Matthew Paull | Air Products and | 69 | |
| Brian Gilvary | Air Liquide SA | 54 | |
| Lionel Nowell | Ecolab Inc | 66 | |
Management Performance
| Return On Equity | 0.28 | |||
| Return On Asset | 0.11 |
Novozymes AS B Leadership Team
Elected by the shareholders, the Novozymes' board of directors comprises two types of representatives: Novozymes inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Novozymes. The board's role is to monitor Novozymes' management team and ensure that shareholders' interests are well served. Novozymes' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Novozymes' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Thomas Videbaek, COO and Executive VP of Bus. Devel. | ||
| Tobias Bjorklund, Head of Investor Relations | ||
| Ester Baiget, Pres CEO | ||
| Kasim Kutay, Director | ||
| Anders Lund, Executive Vice President Household Care & Technical Industries | ||
| Agnete RaaschouNielsen, Director | ||
| Thomas Nagy, Executive VP of Supply Operations | ||
| Pedro Fernandes, Head America | ||
| Joergen Rasmussen, Independent Director | ||
| Andrew Fordyce, Executive VP of Food and Beverages | ||
| Lena Halskov, Director, Employee Representative | ||
| Tue Micheelsen, VP Marketing | ||
| Sebastian Sderberg, VP Acquisitions | ||
| Martin Riise, Head of Investor Relations | ||
| Peder Nielsen, CEO and Pres | ||
| Prisca HavranekKosicek, CFO | ||
| HeinzJuergen Bertram, Independent Director | ||
| Benny Loft, CFO and Executive VP | ||
| Anders Knudsen, Director, Employee Representative | ||
| Lena Olving, Independent Director | ||
| Mathias Uhlen, Independent Director | ||
| Graziela Malucelli, Supply Operations | ||
| Patricia Malarkey, Director | ||
| Henrik Gurtler, Chairman of the Board | ||
| Per Falholt, Consultant | ||
| Kim Stratton, Director | ||
| Tina Fanoe, Executive Vice President Agriculture & Bioenergy | ||
| Lena Holskov, Director, Employee Representative | ||
| Morten Rasmussen, Sustainability People | ||
| Thomas Bomhoff, Head of Investor Relations | ||
| Lars Green, Director | ||
| MSc MSc, Ex CFO | ||
| Lars Koeppler, Independent Director, Employee Representative |
Novozymes Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Novozymes a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.28 | |||
| Return On Asset | 0.11 | |||
| Profit Margin | 0.21 % | |||
| Operating Margin | 0.26 % | |||
| Current Valuation | 14.47 B | |||
| Shares Outstanding | 222.86 M | |||
| Shares Owned By Insiders | 8.04 % | |||
| Shares Owned By Institutions | 42.30 % | |||
| Price To Earning | 33.38 X | |||
| Price To Book | 6.19 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Novozymes AS B. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population. You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.
Complementary Tools for Novozymes Pink Sheet analysis
When running Novozymes' price analysis, check to measure Novozymes' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novozymes is operating at the current time. Most of Novozymes' value examination focuses on studying past and present price action to predict the probability of Novozymes' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novozymes' price. Additionally, you may evaluate how the addition of Novozymes to your portfolios can decrease your overall portfolio volatility.
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal |